PDX model details
| PDX ID |
424M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
6 |
| Average PDX Generation Time (days +/- SEM) |
136 ± 38 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
424M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
Y |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 424M |
CDKN1B |
-1.590 |
0.664 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
PTEN |
-23.821 |
1.350e-07 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
AR |
4.638 |
24.898 |
Gain-High
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
FANCD2 |
0.522 |
2.872 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
RAF1 |
0.522 |
2.872 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
MET |
0.689 |
3.225 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
BRAF |
0.676 |
3.196 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
EZH2 |
0.676 |
3.196 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
CHD7 |
0.979 |
3.943 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
MYC |
1.274 |
4.838 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 424M |
GNAS |
0.536 |
2.900 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
424M |
| Sample Site |
Lymph node |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, zoladex and cosudex |
| |
|
Patient Information
| Patient Number |
424 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
No information in Gene expression
No information in Drug dosing Table